

GLAXOSMITHKLINE PLC

Form 6-K

April 17, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 17 April 2018

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms E Walmsley  
 b) Position/status Chief Executive Officer

- c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
 ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018.

- c) Price(s) and volume(s)  
 Price(s) Volume(s)  
 £14.3999 1885.380  
 n/a (single transaction)

Aggregated information

- d) Aggregated volume Price

- e) Date of the transaction 2018-04-12  
 f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr R G Connor  
 b) Position/status President, Global Manufacturing & Supply  
 c) Initial notification/  
 Initial notification

amendment

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£14.3999	820.907
n/a (single transaction)	

Aggregated information

- d) Aggregated volume Price
- e) Date of the transaction 2018-04-12
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr L Debruyne
  - b) Position/status President, Global Vaccines
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

April 2018.

c) Price(s) and volume(s)  
 Price(s)      Volume(s)  
 £14.3999      1360.326  
 n/a (single transaction)

Aggregated information

d) Aggregated volume Price

e) Date of the transaction      2018-04-12  
 f) Place of the transaction      London Stock Exchange  
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name      Mr S Dingemans  
 b) Position/status      Chief Financial Officer  
 c) Initial notification/  
 amendment      Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name      GlaxoSmithKline plc  
 b) LEI      5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument      Ordinary shares of 25 pence  
 each ('Ordinary Shares')  
 ISIN: GB0009252882

b) Nature of the transaction      Acquisition of Ordinary  
 Shares following the  
 re-investment of dividends  
 paid to shareholders on 12  
 April 2018.

c) Price(s) and volume(s)  
 Price(s)      Volume(s)  
 £14.3999      1289.846  
 n/a (single transaction)

Aggregated information

d) Aggregated volume Price

e) Date of the transaction      2018-04-12  
 f) Place of the transaction      London Stock Exchange  
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr D S Redfern
  - b) Position/status Chief Strategy Officer
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£14.3999	2388.623
n/a (single transaction)	
  - d) Aggregated information  
Aggregated volume Price
  - e) Date of the transaction 2018-04-12
  - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Ms C Thomas
  - b) Position/status SVP, HR
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018.
- c) Price(s) and volume(s)
- |                          |           |
|--------------------------|-----------|
| Price(s)                 | Volume(s) |
| £14.3999                 | 1514.507  |
| n/a (single transaction) |           |

- d) Aggregated information
- Aggregated volume Price

- e) Date of the transaction 2018-04-12
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr P C Thomson  
President, Global Affairs
- b) Position/status
- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument
- |            |  |
|------------|--|
| Instrument | Ordinary shares of 25 pence each ('Ordinary Shares') |
| ISIN       | GB0009252882   |

- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018.
- c) Price(s) and volume(s)
- |                          |           |
|--------------------------|-----------|
| Price(s)                 | Volume(s) |
| £14.3999                 | 1262.984  |
| n/a (single transaction) |           |

Aggregated volume Price

- e) Date of the transaction 2018-04-12  
 f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mrs K Thomson  
 b) Position/status PCA of Mr P C Thomson (President, Global Affairs)

- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
 ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018.

- c) Price(s) and volume(s)  
 Price(s) Volume(s)  
 £14.3999 156.475  
 n/a (single transaction)

Aggregated information

- d) Aggregated volume Price

- e) Date of the transaction 2018-04-12  
 f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr N Hirons  
 b) Position/status SVP, Global Ethics and Compliance

- c) Initial notification/ amendment Initial notification

2.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018.

c) Price(s) and volume(s)  
Price(s) Volume(s)  
£14.3999 380.094  
n/a (single transaction)

d) Aggregated information  
Aggregated volume Price

e) Date of the transaction 2018-04-12  
f) Place of the transaction London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: April 17, 2018

By: VICTORIA WHYTE-

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc